CureVac Statistics

Total Valuation

CureVac has a market cap or net worth of EUR 1.05 billion. The enterprise value is 683.70 million.

Market Cap	1.05B
Enterprise Value	683.70M

Important Dates

The last earnings date was Friday, August 15, 2025.

Earnings Date	Aug 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	225.17M
Shares Outstanding	n/a
Shares Change (YoY)	+0.17%
Shares Change (QoQ)	+1.74%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	125.87M

Valuation Ratios

The trailing PE ratio is 5.44.

PE Ratio	5.44
Forward PE	n/a
PS Ratio	2.06
PB Ratio	1.80
P/TBV Ratio	1.88
P/FCF Ratio	5.35
P/OCF Ratio	5.16
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.01, with an EV/FCF ratio of 3.47.

EV / Earnings	3.53
EV / Sales	1.41
EV / EBITDA	3.01
EV / EBIT	3.24
EV / FCF	3.47

Financial Position

The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.06.

Current Ratio	6.17
Quick Ratio	5.89
Debt / Equity	0.06
Debt / EBITDA	0.14
Debt / FCF	0.18
Interest Coverage	597.63

Financial Efficiency

Return on equity (ROE) is 40.22% and return on invested capital (ROIC) is 28.93%.

Return on Equity (ROE)	40.22%
Return on Assets (ROA)	24.11%
Return on Invested Capital (ROIC)	28.93%
Return on Capital Employed (ROCE)	38.70%
Revenue Per Employee	564,722
Profits Per Employee	214,201
Employee Count	983
Asset Turnover	0.82
Inventory Turnover	52.72

Taxes

In the past 12 months, CureVac has paid 26.75 million in taxes.

Income Tax	26.75M
Effective Tax Rate	12.14%

Stock Price Statistics

The stock price has increased by +53.86% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+53.86%
50-Day Moving Average	4.64
200-Day Moving Average	3.49
Relative Strength Index (RSI)	74.76
Average Volume (20 Days)	53

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CureVac had revenue of EUR 510.51 million and earned 193.64 million in profits. Earnings per share was 0.86.

Revenue	510.51M
Gross Profit	484.20M
Operating Income	240.25M
Pretax Income	220.39M
Net Income	193.64M
EBITDA	252.02M
EBIT	240.25M
Earnings Per Share (EPS)	0.86

Full Income Statement

Balance Sheet

The company has 392.70 million in cash and 36.03 million in debt, giving a net cash position of 356.67 million.

Cash & Cash Equivalents	392.70M
Total Debt	36.03M
Net Cash	356.67M
Net Cash Per Share	n/a
Equity (Book Value)	586.37M
Book Value Per Share	2.56
Working Capital	351.76M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 204.08 million and capital expenditures -7.04 million, giving a free cash flow of 197.04 million.

Operating Cash Flow	204.08M
Capital Expenditures	-7.04M
Free Cash Flow	197.04M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 94.85%, with operating and profit margins of 47.06% and 37.93%.

Gross Margin	94.85%
Operating Margin	47.06%
Pretax Margin	43.17%
Profit Margin	37.93%
EBITDA Margin	49.37%
EBIT Margin	47.06%
FCF Margin	38.60%

Dividends & Yields

CureVac does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.17%
Shareholder Yield	n/a
Earnings Yield	18.38%
FCF Yield	18.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	7